NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

3,013
Mkt Cap
$1.96B
Volume
1,287.00
52W High
$9.75
52W Low
$1.54
PE Ratio
-8.90
NUVB Fundamentals
Price
$5.64
Prev Close
$5.70
Open
$5.72
50D MA
$7.52
Beta
1.53
Avg. Volume
6.39M
EPS (Annual)
-$2.11
P/B
6.00
Rev/Employee
$35,786.36
Loading...
Loading...
News
all
press releases
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced finalization of a protocol amendment to the ongoing...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) has been given an average rating of "Moderate Buy" by the twelve analysts that are currently covering the stock, Marketbeat reports. One research...
MarketBeat·18d ago
News Placeholder
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2% - Here's Why
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2% - What's Next...
MarketBeat·19d ago
News Placeholder
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround
Nuvation Bio (NUVB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks·28d ago
News Placeholder
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts
read more...
Benzinga·29d ago
News Placeholder
Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade
Nuvation Bio (NYSE:NUVB) Shares Gap Down Following Analyst Downgrade...
MarketBeat·29d ago
News Placeholder
HC Wainwright Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price
HC Wainwright reduced their price objective on shares of Nuvation Bio from $18.00 to $17.00 and set a "buy" rating on the stock in a research note on Monday...
MarketBeat·29d ago
News Placeholder
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced preliminary fourth quarter and full year 2025 net...
Business Wire·29d ago
News Placeholder
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., Nuvation Bio), a global oncology company focused on tackling some of the toughest challenges in cancer...
Business Wire·29d ago
News Placeholder
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief...
Business Wire·1mo ago
<
1
2
...
>

Latest NUVB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.